Ferumoxytol well tolerated in Merrimack Phase I trial

|About: Merrimack Pharmaceuticals (MACK)|By:, SA News Editor

AMAG Pharmaceuticals' Ferumoxytol, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to treatment with the company's MM-398 cancer therapy in a Phase I trial conducted by Merrimack Pharmaceuticals (MACK).

Almost all the tumor lesions that shrank after MM-398 treatment were associated with higher levels of ferumoxytol, MACK says.

Shares are +1.4%. (PR)

This was corrected on 04/08/2014 at 03:05 PM. The owner of Ferumoxytol was incorrectly stated as MACK.